Additionally, Goel demonstrated that CDK4 inhibition activates anti-tumor immunity [44]; therefore it is of interest to treat STS patients with combined therapy including CDK4/6 inhibitor and immune-checkpoint inhibitor. Here, CDK4 is linked to telomere syndrome.